Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142661 · ClinicalTrials.gov registry record · NA
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
A NA study, sponsored by Eisai.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01142661 is a NA study that has completed, run by Eisai. The registered enrollment target is 9 participants.
The verdict
NCT01142661, a NA study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
Interventions
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142661
The ClinicalTrials.gov registry entry for NCT01142661 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eribulin Mesylate is the first listed.
NCT01142661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142661 about?
NCT01142661 is a clinical study titled "Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies". The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
What is the current status of trial NCT01142661?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2010-08.
What interventions are being tested in trial NCT01142661?
The interventions under investigation include: Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT01142661?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.